United Therapeutics Corporation
NASDAQ:UTHRBiotechnology
-$18.01 today
- Market cap
- $24.59B
- Beta
- 0.57
- P/E (TTM)
- 18.0
- EPS (TTM)
- $29.60
Volume 0.42M
Average 0.52M
UTHR Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
United Therapeutics CorporationNASDAQ: UTHR
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows in line with its trailing trend
Q2 FY2026 depreciation & amortization of $24.2M rose 14.7% year over year, in line with the +14.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 7.1% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.
Context
- Depreciation & amortization amounted to 2.7% of revenue in FY2025, up 0.2 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +14.7% toward the trailing-twelve-month pace of +14.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 85.6M USD
- Year-over-year change
- +18.1%
- 4-year CAGR
- +14.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 85.6M | +18.1% |
| FY2024 | 2024-12-31 | 72.5M | +36.3% |
| FY2023 | 2023-12-31 | 53.2M | +3.7% |
| FY2022 | 2022-12-31 | 51.3M | +2.8% |
| FY2021 | 2021-12-31 | 49.9M | — |
Depreciation & Amortization vs competitors
How UTHR compares with its peers on the latest reported figures
- UTHR's LTM Jun 2026 depreciation & amortization of $91.5M is the largest of the 5 companies compared; the peer median is $10.71M.
- Its year-over-year change of +14.8% is the 3rd highest of 5, against a peer median of +22.2%.
- Depreciation & amortization amounts to 2.9% of revenue for UTHR, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $91.5M | +14.8% | +18.6% | 2.9% | |
| LTM Sep 2026 | $52.78M | -3.5% | +43.1% | 8.1% | |
| LTM Jun 2026 | $19.73M | +59.7% | +16.8% | 1.7% | |
| LTM Jun 2026 | $1.69M | -9.0% | -25.2% | 0.4% | |
| LTM Mar 2026 | $47.85K | +47.9% | +108.0% | — | |
| Peer median (excluding UTHR) | $10.71M | +22.2% | +29.9% | 1.7% | |
Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 475.8M | 727.3M | 984.8M | 1.2B | 1.33B |
| Depreciation & Amortization | 49.9M | 51.3M | 53.2M | 72.5M | 85.6M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 97.7M |
| Stock-Based Compensation | 138.5M | 106.8M | 39.1M | 144M | 147.7M |
| Change in Working Capital | (174.2M) | (141.2M) | (97.8M) | (60.2M) | (106.4M) |
| Accounts Receivables | (41.3M) | (21.7M) | (58.5M) | (400K) | (70.9M) |
| Inventory | (7.5M) | (13.4M) | (13.6M) | (46.9M) | (52.6M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 97.9M |
| Other Working Capital | (125.4M) | (106.1M) | (25.7M) | (12.9M) | (80.9M) |
| Other Non-Cash Items | 108.2M | 58.3M | (1.3M) | (24.3M) | 2M |
| Operating Cash Flow | 598.2M | 802.5M | 978M | 1.33B | 1.56B |
| Capital Expenditures | (120.8M) | (138.8M) | (230.4M) | (246.5M) | (520.5M) |
| Acquisitions (Net) | 0 | (1.5M) | (89.2M) | (30.5M) | 0 |
| Purchases of Investments | (1.9B) | (1.71B) | (2.51B) | (1.65B) | (3.46B) |
| Sales of Investments | 1.53B | 1.03B | 2.14B | 2.37B | 1.58B |
| Other Investing Activities | 0 | 3.5M | (23M) | (28.5M) | 1.85B |
| Investing Cash Flow | (486.9M) | (811.5M) | (719.6M) | 417.2M | (551.3M) |
| Debt Repayment | 0 | 0 | (100M) | (400M) | (300M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 183.1M |
| Common Stock Repurchased | (10.8M) | (11.4M) | (13.8M) | (1.01B) | (1B) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 55.6M | 86.8M | 101.9M | 157.4M | (33.1M) |
| Financing Cash Flow | 44.8M | 75.4M | (11.9M) | (1.25B) | (1.15B) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 156.1M | 66.4M | 246.5M | 489.5M | (140.1M) |
| Free Cash Flow | 477.4M | 663.7M | 747.6M | 1.08B | 1.04B |
United Therapeutics Corporation
NASDAQ:UTHR
Intrinsic Alpha fair value
Locked
Current Price
$577.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.